MedTrace Logo

A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery

NCT03687931 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-05-24

No results posted yet for this study

Summary

Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.

Conditions

  • Inflammation Eye

Interventions

DRUG

Dexamethasone

Drop

Sponsors & Collaborators

  • iDrop, Inc.

    lead INDUSTRY

Principal Investigators

  • William White · iDrop, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-26
Primary Completion
2019-02-28
Completion
2019-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03687931 on ClinicalTrials.gov